Rare Disease Economics: Why Small Patient Populations Can Still Build Large Companies

A Counterintuitive Pattern

Before the US Orphan Drug Act passed in 1983, fewer than forty drugs had ever been developed specifically for rare diseases — the commercial logic simply did not work when a patient population numbered in the hundreds or low thousands worldwide, and a pharmaceutical company weighing where to allocate its finite research budget had no rational reason to choose a disease with a few thousand patients over one with a few million. More than six hundred orphan drugs have reached patients in the four decades since, at an accelerating pace, and the global orphan drug market reached an estimated $217 billion in 2025.

Read those two facts together and a genuinely counterintuitive pattern emerges: an entire industry built on the premise of commercial impossibility has become one of pharma’s most resilient and fastest-growing franchises, even as it still reaches only an estimated 5 percent of the more than seven thousand known rare diseases. That last figure is worth sitting with on its own — a $217 billion market represents genuine, large-scale commercial success, and it is still, by the industry’s own accounting, addressing less than one-twentieth of the underlying problem it exists to solve.

The Regulatory Architecture That Made It Possible

The regulatory architecture explains most of the shift, and it is worth itemizing precisely because the incentive package is genuinely unusual relative to how the rest of the pharmaceutical industry is regulated. The Orphan Drug Act and its international equivalents — the EMA offers a broadly parallel framework in Europe — provide seven years of US market exclusivity upon approval, extending to ten years or more under the EU’s regime, compared to five years for a conventional drug, a meaningfully longer runway during which no competitor can launch a generic or biosimilar version regardless of patent status.

They add a 25 percent tax credit on qualifying clinical trial expenses, a waiver of FDA application fees that can otherwise exceed $3 million, and dedicated regulatory assistance for the genuinely hard problem of designing a statistically valid trial around a patient population too small to support a conventional randomized study — a population of, say, two thousand patients worldwide simply cannot support the same trial design as a population of two million, and the FDA’s Office of Orphan Products Development exists specifically to help sponsors design smaller, methodologically sound trials that a conventional biostatistics team, trained on large-population trial design, might not otherwise know how to construct defensibly.

Priority Review, Breakthrough Therapy, and Accelerated Approval designations are disproportionately available to orphan programs, meaningfully compressing development timelines relative to the rest of the industry, and collectively these incentives do something that is easy to state simply but hard to overstate in importance: they convert what would otherwise be an economically irrational R&D allocation decision into a genuinely attractive one, at least for the specific rare diseases the incentive package covers well.

The Pricing Tension

The pricing consequence of all that risk reduction is premium pricing, and it is worth being direct about the tension that creates rather than glossing over it. Analysts project each of 2026’s top ten orphan blockbusters will individually generate between three and thirteen billion dollars in annual revenue — numbers that would have seemed implausible for a drug treating a few thousand patients worldwide, until you account for pricing that reflects both genuine development risk and, increasingly, payer scrutiny that has begun pushing back specifically on orphan drugs serving larger rare-disease populations, above roughly one hundred thousand patients, where the traditional small-population pricing logic starts to look harder to justify.

That distinction — between a genuinely ultra-rare disease affecting a few hundred patients and a larger “rare” disease affecting closer to a hundred thousand — is where much of the coming policy and reimbursement friction in this category will concentrate. A price point that is uncontroversial for a disease affecting three hundred patients worldwide becomes a considerably harder political and actuarial conversation when applied to a disease affecting three hundred thousand, even though both technically qualify under the same orphan-designation threshold, and payers across every major market are increasingly drawing exactly that distinction in how they negotiate.

Where the M&A Capital Is Actually Flowing

BioMarin’s two 2025 acquisitions — Amicus Therapeutics for $4.8 billion and Inozyme Pharma for $270 million — illustrate where consolidation capital is actually flowing within the category: toward complementary rare-disease portfolios that can share commercial infrastructure, patient-identification networks, and regulatory expertise across multiple small-population indications, rather than toward single-asset companies with one shot on goal.

That is a meaningfully different M&A logic from the rest of biotech, where a single blockbuster asset can justify an acquisition on its own; in rare disease, the platform and the patient-finding infrastructure increasingly matter as much as any individual molecule, because identifying and enrolling the several hundred or few thousand patients worldwide who have a given ultra-rare condition is itself a specialized, relationship-and-registry-driven capability that does not automatically come bundled with a promising molecule — a company with strong rare-disease commercial infrastructure can often extract more value from a newly acquired asset than the asset’s original, smaller developer could have on its own.

The Formulation Problem Nobody Talks About

The formulation and clinical-trial-design challenges specific to this category deserve real attention, because they are genuinely distinct problems from mainstream drug development, not smaller versions of the same problem. A disease affecting ten thousand patients globally cannot support the large-scale, iterative dose-optimization trials that guide conventional formulation development, where a developer might test a dozen different dose levels across thousands of patients to find the optimal balance of efficacy and tolerability. Rare diseases skew heavily pediatric, which adds its own dosage-form and safety-monitoring complexity — a drug that needs to be dosed precisely by body weight in very young children, sometimes infants, requires formulation science considerably more exacting than a fixed-dose tablet for an adult population.

Adaptive trial designs, natural-history patient registries built years ahead of any actual clinical program, and genuine international collaboration to pool small national patient populations into trial-viable cohorts have all become necessary infrastructure rather than optional refinements — a natural-history registry, tracking how a rare disease actually progresses in untreated patients before any drug trial begins, has become close to a prerequisite for a credible rare-disease development program, since regulators increasingly want to see a documented, well-characterized disease trajectory against which a trial’s treatment effect can be meaningfully compared. Infrastructure of that kind is, again, a distinct and investable layer separate from any single therapeutic asset, much like the manufacturing infrastructure discussed elsewhere in this issue’s treatment of cell and gene therapy.

Two Developments Worth Watching

Two structural developments deserve specific mention for how they change the calculus going forward. The reauthorization of the Rare Pediatric Disease Priority Review Voucher program in early 2026 restores a genuinely important source of non-dilutive capital for small developers — these vouchers, which grant priority review on an unrelated future drug, have historically sold for hundreds of millions of dollars to larger companies wanting to accelerate their own pipeline, giving a cash-constrained rare-disease company a real monetization path even before its own drug reaches the market, effectively letting a small company convert a regulatory designation into working capital well ahead of any product revenue.

And gene editing platforms are increasingly positioned as a curative, one-time-treatment alternative to chronic enzyme-replacement or symptom-management therapies for a meaningful subset of genetic rare diseases, which could fundamentally restructure the pricing and reimbursement conversation for the categories where it succeeds clinically — a payer evaluating a single, curative gene-editing treatment priced at several million dollars is, in principle, comparing that cost against decades of ongoing enzyme-replacement therapy that may itself total a comparable or larger sum over a patient’s lifetime, a genuinely different actuarial calculation than pricing has historically had to accommodate in this category.

The Honest Risk Factors

The honest risk factors are worth stating plainly rather than glossing over. FDA decision-making in this category has proven genuinely unpredictable at times, particularly around programs relying on external control arms rather than randomized trials against a placebo — a design choice rare-disease developers frequently have no real alternative to, given how few patients exist to randomize in the first place, since withholding treatment from half of an already tiny eligible patient population is often neither ethically nor practically feasible. And rare-disease programs increasingly compete for capital and attention against obesity and other large-population disease areas where the addressable market, and the headline-grabbing clinical data, is simply larger — a genuine allocation tension within venture and pharma R&D budgets alike, as the obesity category’s own outsized data, discussed at length elsewhere in this issue, continues to pull capital and talent toward itself.

What a Concentrated Portfolio Should Take From This

For a concentrated portfolio, rare disease offers something genuinely distinct from the rest of the healthcare venture landscape: a regulatory and pricing environment engineered specifically to make small-population economics work, evidence that the model produces genuine multi-billion-dollar outcomes rather than merely academic interest, and a category still reaching only one in twenty of the diseases it theoretically could. That combination of favorable structural economics and vast remaining white space is a rarer pairing in healthcare venture than the category’s modest size in most fund allocations would suggest, and it is exactly the kind of asymmetry a fund with the patience to underwrite a genuinely long development timeline should be actively hunting for rather than treating as a niche allocation.